Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Crescent Biopharma (CBIO) Amortization of Deferred Charges (2019 - 2021)

Crescent Biopharma has reported Amortization of Deferred Charges over the past 2 years, most recently at $189440.0 for Q3 2021.

Quarterly Amortization of Deferred Charges rose 10.08% to $189440.0 in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $731302.0 through Sep 2021, changed N/A year-over-year, with the annual reading at $680845.0 for FY2020, 9.8% up from the prior year.
Amortization of Deferred Charges was $189440.0 for Q3 2021 at Crescent Biopharma, up from $184935.0 in the prior quarter.
Over five years, Amortization of Deferred Charges peaked at $189440.0 in Q3 2021 and troughed at $164262.0 in Q1 2020.